TransPharma Medical

TransPharma Medical is a specialty pharmaceutical company focused on the development and commercialization of drugs, with an emphasis on utilizing its proprietary active transdermal drug delivery technology to develop and commercialize pharmaceuticals. The company aims to develop a range of drug products through strategic collaborations with leading pharmaceutical companies as well as independent product development. Their current proprietary drug product development pipeline includes ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product for the treatment of osteoporosis, which is undergoing Phase 2B clinical trials developed in collaboration with Eli Lilly, along with two additional peptides currently in Phase I.